Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus

被引：78

作者：

Cuenca-Estrella, M ^{[1
]}

Rodríguez-Tudela, JL ^{[1
]}

Mellado, E ^{[1
]}

Martínez-Suárez, JV ^{[1
]}

Monzón, A ^{[1
]}

机构：

[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Micol, Madrid 28220, Spain

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1998年 / 42卷 / 04期

关键词：

D O I：

10.1093/jac/42.4.531

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Voriconazole was compared with amphotericin B and itraconazole by a modification of the NCCLS microdilution reference method for yeasts against 62 clinical isolates of Aspergillus fumigatus. MICs of voriconazole were slightly lower than those of amphotericin B and itraconazole. The MIC of voriconazole at which 90% of isolates were inhibited was 1 mg/L and the MIC range was 0.25-2 mg/L. Voriconazole is a new antifungal agent with potential for use in the treatment of A. fumigatus infections.

引用

页码：531 / 533

页数：3

共 10 条

[1]

BENNETT JE, 1995, PRINCIPLES PRACTICE, P2306

[2] Itraconazole resistance in Aspergillus fumigatus [J].

Denning, DW ;

Venkateswarlu, K ;

Oakley, KL ;

Anderson, MJ ;

Manning, NJ ;

Stevens, DA ;

Warnock, DW ;

Kelly, SL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1364-1368

[3] Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi [J].

EspinelIngroff, A ;

Bartlett, M ;

Bowden, R ;

Chin, NX ;

Cooper, C ;

Fothergill, A ;

McGinnis, MR ;

Menezes, P ;

Messer, SA ;

Nelson, PW ;

Odds, FC ;

Pasarell, L ;

Peter, J ;

Pfaller, MA ;

Rex, JH ;

Rinaldi, MG ;

Shankland, GS ;

Walsh, TJ ;

Weitzman, I .

JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :139-143

[4] Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis [J].

George, D ;

Miniter, P ;

Andriole, VT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) :86-91

[5] Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs [J].

Martin, MV ;

Yates, J ;

Hitchcock, CA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :13-16

[6] In vitro evaluation of voriconazole against some clinically important fungi [J].

McGinnis, MR ;

Pasarell, L ;

Sutton, DA ;

Fothergill, AW ;

Cooper, CR ;

Rinaldi, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1832-1834

[7] Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis [J].

Murphy, M ;

Bernard, EM ;

Ishimaru, T ;

Armstrong, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :696-698

[8]

*NAT COMM CLIN LAB, 1997, N27A NCCLS

[9] IMPROVED MEDIUM FOR FLUCONAZOLE SUSCEPTIBILITY TESTING OF CANDIDA-ALBICANS [J].

RODRIGUEZTUDELA, JL ;

MARTINEZSUAREZ, JV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) :45-48

[10]

Schwartz S, 1997, BRIT J HAEMATOL, V97, P663, DOI 10.1046/j.1365-2141.1997.972911.x

← 1 →